title: Prospects for HIV-1 therapeutic immunisation and vaccination: the potential contribution of peptide immunogens.
abstract: BACKGROUND
  Human immunodeficiency virus (HIV)-1 infection continues to challenge the development of antigen-specific immune-based strategies for the management (therapeutic immunisation) and prevention (vaccination) of HIV-1 infection.
  
  
  OBJECTIVE
  This review aims to assess current prospects for HIV-1 therapeutic immunisation with particular emphasis on the contribution of peptide-based immunogens.
  
  
  METHODS
  The potential for therapeutic immunisation to provide immunological support that can allow for prolonged safe ART-free periods is discussed in light of the Strategies for Management of Antiretroviral Therapy (SMART) study. Different approaches to peptide design are considered including the quality of T-cell responses desired.
  
  
  CONCLUSIONS
  Synthetic peptide immunogens are amenable to modification to improve immunogenicity and reactivity to multiple virus subtypes. Ideally peptide immunogens should incorporate combinations that target restricted, relevant polyfunctional epitopes to regions of HIV-1 associated with control of infection. Peptides showing a beneficial effect following therapeutic immunisation may provide the basis for a future preventative vaccine.
authors.affiliation: Director of Research Bionor Immuno AS, Klostergata 33, NO-3732 Skien, Norway. ms@bionorimmuno.com
authors.forename: Maja A
authors.initials: MA
authors.lastname: Sommerfelt
authors.forename: Birger
authors.initials: B
authors.lastname: Sørensen
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D015195:Drug Design; D024921:Drug Resistance, Multiple, Viral; D000939:Epitopes / Q000276:immunology; D005544:Forecasting; D015488:HIV Antigens / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D016233:Immunotherapy, Active / Q000639:trends*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014611:Vaccination / Q000379:methods; D022223:Vaccines, Subunit / Q000276:immunology / Q000627:therapeutic use
chemical_list: D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D000939:Epitopes; D015488:HIV Antigens; D006680:HLA Antigens; D022223:Vaccines, Subunit